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Abstract
CPT-11 belongs to the class of topoisomerase I inhibi-
tors, and it acts as a prodrug of SN-38, which is approxi-
mately 100–1000-fold more cytotoxic than the parent drug.
CPT-11 has shown a broad spectrum of antitumor activity
in preclinical models as well as clinically, with responses
observed in various disease types including colorectal, lung,
cervical, and ovarian cancer. The pharmacokinetics and
metabolism of CPT-11 are extremely complex and have been
the subject of intensive investigation in recent years. Both
CPT-11 and SN-38 are known in an active lactone form and
an inactive carboxylate form, between which an equilibrium
exists that depends on the pH and the presence of binding
proteins. CPT-11 is subject to extensive metabolic conver-
sion by various enzyme systems, including esterases to form
SN-38, UGT1A1 mediating glucuronidation of SN-38, as
well as CYP3A4, which forms several pharmacologically
inactive oxidation products. Elimination routes of CPT-11
also depend on the presence of drug-transporting proteins,
notably P-glycoprotein and canalicular multispecific organic
anion transporter, present on the bile canalicular mem-
brane. The various processes mediating drug elimination,
either through metabolic breakdown or excretion, likely
impact substantially on interindividual variability in drug
handling. Strategies to individualize CPT-11 administration
schedules based on patient differences in enzyme or protein
expression or by coadministration of specific agents modu-
lating side effects are under way and may ultimately lead to
more selective chemotherapeutic use of this agent.
Introduction
Camptothecin, a plant alkaloid isolated from Camptotheca
acuminata (family Nyssaceae), was first discovered in the early
1960s (1). Because of severe and unpredictable side effects of
camptothecin in early clinical studies, clinical development was
halted in the 1970s (2–5). It was later revealed that the water
insolubility of camptothecin was an important factor mediating
the unpredictable toxic effects (6). The elucidation of the mech-
anism of action of camptothecin, i.e., inhibition of topoisomer-
ase I, a nuclear enzyme which relaxes torsionally strained (super
coiled) DNA (7–9), resulted in renewed interest in this agent,
and subsequently, numerous derivatives have been synthesized
and tested clinically (10–12). Some of these agents, including
CPT-113 (13), topotecan (14), 9-aminocamptothecin and 9-
nitrocamptothecin (15–17), lurtotecan (GI147211, GG211; Ref.
18), and DX-8951f (19), have a broad spectrum of antitumor
activity both in vitro and in vivo and show more predictable and
clinically manageable toxicities than the originally isolated
structure. Two of these agents, topotecan and CPT-11, have
recently been introduced into clinical practice for the treatment
of ovarian and colorectal cancer, respectively. Of the currently
available camptothecin analogues, CPT-11 has an extremely
complex pharmacological profile, which is dependent on a host
of enzymes involved in metabolic transformation and active
transport proteins, regulating intestinal absorption and hepato-
biliary secretion mechanisms (Fig. 1). Furthermore, CPT-11 is
chemically unique because of the presence of a bulky side chain
on the core structure, the enzymatic cleavage of which is a
requirement for pharmacological activity. In addition, CPT-11 is
known in two distinguishable forms, an active -hydroxy--
lactone ring form and an inactive carboxylate form, between
which a pH-dependent equilibrium exists (12) that significantly
impacts on the kinetic profile of the compound. In recent years,
a wealth of information has become available that has substan-
tially aided in our understanding of the clinical actions of this
agent. Here, we will review the clinical pharmacokinetic prop-
erties of CPT-11 and its metabolites that appear to be crucial for
optimal anticancer chemotherapeutic use.
Pharmacokinetic Properties
Plasma Disposition. The plasma pharmacokinetics of
CPT-11 in humans has now been addressed in several studies,
and taking into account that these data are from different labo-
ratories, the results are fairly comparable. Most of the initial
studies have been performed with the drug administered as a
short i.v. infusion (0.5–1.5 h). After such administration, peak
plasma concentrations were reached at the end of infusion
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(20–36), with a rapid decrease thereafter as a result of multiple
distribution and elimination pathways (32, 36). A rebound peak
in the concentration-curve has been noticed in some studies (22,
26, 31, 36) and was initially ascribed to enterohepatic recircu-
lation (22, 26). More recently, it has been suggested that this
phenomenon is related to substantial uptake of CPT-11 lactone
by erythrocytes and its subsequent release, followed by accu-
mulation of the carboxylate form in the plasma compartment
(37). Equilibrium between the two drug forms is rapidly estab-
lished, and contrary to CPT-11, the principal metabolite SN-38
predominates in its active lactone form (33, 34). The lactone
form of SN-38 accounts for approximately 60–70% of total
plasma SN-38 after the end of a CPT-11 infusion, declining to
of 33–66% at equilibrium (23, 33). The mean lactone:total AUC
ratio of SN-38 is high, 64%, albeit with large interpatient
variability (23, 24, 33, 34, 38). This ratio remains constant for
the whole dose range measured. Examples of concentration-time
profiles for the lactone and carboxylate forms of CPT-11 and
SN-38 are shown in Fig. 2.
The peak concentration of CPT-11 appears to be dose-
proportional in a large dose range (100–750 mg/m2), although
substantial interpatient variability has been noted (21–23, 25,
26, 39, 40). This variability increases at later time points (41).
CPT-11 systemic exposure or AUC also increases in a dose-
independent way at doses ranging from 33 to 180 mg/m2 (24–
26, 39, 40, 42), indicating linear pharmacokinetics.
The ratio of the lactone:total AUC remains relatively con-
stant over the entire dose range of CPT-11, with mean values
ranging from 34  5% up to 44  4% (33, 34). The conversion
of the lactone into the carboxylate form of CPT-11 is rapid, with
a mean half-life of 9.5 min (34). The plasma profiles of the two
forms of CPT-11 are comparable and can best be fitted in a bi-
or tri-exponential equation (22, 25, 43), with mean terminal
half-life values of about 9.3–14.2 h (22, 25, 35). More recently,
it has been suggested that the terminal disposition half-life of
Fig. 2 Plasma concentration-time profiles of the lactone (‚, E) and
total drug (i.e., lactone plus carboxylate) forms of CPT-11 (‚, Œ) and
SN-38 (E, F) in a group of 17 patients receiving CPT-11 at 200 mg/m2
as a 90-min i.v. infusion. All pharmacokinetic curves were fit to a
three-exponential equation, using Siphar version 4.0 (InnaPhase, Phila-
delphia, PA), assuming a three-compartmental model for distribution
and elimination of the compounds. Data are presented as means;
bars, SD. Data were obtained from Mathijssen et al. (38).
Fig. 1 Metabolic pathways
of CPT-11 showing CE-medi-
ated formation of the active
metabolite SN-38 and its sub-
sequent conversion to a glu-
curonide derivative (SN-38G)
by UGT1A1 and 1A7 isoforms
(UGT1A7), with deglucuronida-
tion by intestinal -glucuroni-
dase (-Glu). CPT-11 can also
undergo CYP3A4-mediated oxi-
dative metabolism to form APC
and NPC, of which the latter can
be hydrolyzed by CE to release
SN-38.
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CPT-11 is much longer, which may be related to the fact that
prolonged sampling schedules were applied in combination with
a highly sensitive detection method (20, 43).
The volume of distribution at steady state of CPT-11 is
large, suggesting extensive tissue distribution, and remained
unchanged with an increase in dose (20, 22, 24, 31). Similarly,
the total plasma clearance of CPT-11 was found to be dose
independent, with a value of 13.5 3.5 L/h/m2 for the total drug
(i.e., lactone plus carboxylate forms) and 45.6 10.8 L/h/m2 for
the lactone form (35). The clearance is unaltered during repeated
cycles, despite a mean interpatient variability of30% (21, 35),
and an intra-patient variability of 13.5%.
Plasma Protein Binding. An important factor in the
pharmacology of drugs is its binding to plasma proteins. In
accordance with the hydrophilic nature of CPT-11, in blood,
80% of the drug is mainly bound to and/or localized in eryth-
rocytes, whereas SN-38 is bound for at least 99%, mainly to
albumin and lymphocytes, but also to erythrocytes and neutro-
phils (44). Although binding to plasma proteins appears to be of
subordinate importance for CPT-11, binding of the principal
metabolite SN-38 to plasma proteins in adults and pediatric
patients is thus substantial and independent of (pretherapy)
serum albumin levels (94–96%; Refs. 44–46). In the presence
of albumin, the lactone forms of CPT-11 and SN-38 are more
stable (47), with higher percentages of the lactone forms avail-
able, compared with the situation without this protein. The
protein binding is not significantly different for the lactone and
carboxylate form of CPT-11. In contrast, SN-38 lactone binds
significantly stronger to albumin than its corresponding carbox-
ylate form, which could explain the better stability of SN-38 in
vivo compared with CPT-11 (47). This, in turn, may play a role
in the differential terminal disposition half-lives and volumes of
distribution between these molecules. In in vitro incubations in
the presence of human serum albumin, the apparent half-life of
the interconversion of CPT-11 is more than three times higher
than that in patients (34). This suggests that there is an early
preferential uptake and/or metabolism of the lactone form of
CPT-11, thereby altering the ratio of CPT-11 lactone versus
carboxylate (34).
Metabolism
Several studies have shown that hepatic metabolism and
biliary secretion are major pathways of CPT-11 elimination in
both animals and humans, with major contributions from vari-
ous classes of enzymes, including CEs, UGTs, CYP3As, and
-glucuronidases.
Esterase-mediated Biotransformation. The conversion
of CPT-11 to SN-38 through cleavage of the ester-bond at C10
by CEs has been studied extensively in recent years. It has been
suggested that two human isozymes of liver CE, i.e., hCE-1 and
hCE-2, have been characterized that might catalyze this conver-
sion (48, 49). No tumor reduction in SQ20b cells was seen after
incubation of CPT-11 with hCE-1, compared with a 60% re-
duction for hCE-2 (49). Therefore, hCE-2 probably plays the
most important role in CPT-11 conversion by CEs in cancer
patients. The plasma of several species, including mouse and
horse, contains high levels of esterases other than CE and it
converts CPT-11 much better into SN-38 than human plasma
does. It has been suggested that butyrylcholinesterase, which
has CPT-11 converting activity, might be responsible for this
phenomenon (50, 51).
SN-38 concentrations have been shown to increase with the
CPT-11 dose over the dose range studied (100–750 mg/m2; Ref.
35). The terminal disposition half lives of SN-38 lactone and
total drug are significantly longer than those of CPT-11 (38, 43).
In an in vitro study of human liver microsomes, twice as much
SN-38 was formed when CPT-11 was present in its lactone form
in comparison with CPT-11 in its carboxylate form (52). Be-
cause CPT-11 lactone is converted easier, this phenomenon
might contribute to the predominance of SN-38 in its lactone
form in plasma (52).
A clear relationship between CE levels and the chemosen-
sitivity of proliferating tissues and cell lines in general has been
suggested (53–55). CPT-11 was significantly more active in five
human small-cell lung cancer cell lines than in four non-small
cell lung cancer cell lines, and this was attributed to a higher CE
activity in the former case (55). CPT-11-converting CE activity
in human tumors has also been studied in vivo (56). A wide
range of variability in enzyme activity in primary colorectal
tumors was seen, with no significant difference between primary
and secondary tumors. Relatively high CE activity in these
tumors, as compared with normal liver tissue has been noticed,
which might suggest a local activation of CPT-11 in tumor
tissues (56). There were no significant differences between
enzyme activity in human liver and colon tissues.
Selective upgrading of CE levels in tumors, thereby pro-
ducing tumor-specific activity may clearly have substantial clin-
ical implications; it will maximize the exposure of tumors to
SN-38 and limit systemic drug concentrations and therefore also
limit adverse effects of CPT-11. This upgrading has been stud-
ied for several enzyme/prodrug combinations, using antibodies
or viruses to attack tumor cells. For the CE/CPT-11 combina-
tion, a recombinant replication-deficient adenovirus vector cod-
ing for human CE cDNA has been developed (57). This vector
effectively suppressed A549 cell growth in vitro in the presence
of CPT-11 by 7–17-fold. Because SN-38 diffuses from the
tumor cell in which it has been produced to its neighbor cells in
growth-suppressive concentrations, only 10% of the A549 cells
need to be infected for a cytotoxic effect in 48% of the cells
(57). In CPT-11-resistant A549 cells, which had a 6-fold resist-
ance and 42% CE activity compared with normal A549 cells,
functional CE expression could be accomplished by infection
with this vector (57, 58), and these resistant cells could be
suppressed efficiently in vitro and in vivo (58). This sensitivity
has also been described for two other human tumor cell lines,
although in another eight human cell lines, only a minimal effect
was seen (59).
In various studies, the activity of CE isozymes from animal
species has been compared with the human enzyme(s), and the
latter show consistently lower activity than those of the other
species investigated (60, 61). Although the active site amino
acids of rabbit and human CEs are almost identical, human CE
converts CPT-11 100–1000-fold less efficiently (59). In Rh30
human rhabdomyosarcoma cells, expression of the rabbit en-
zyme was associated with more rapid tumor regression and a
better prevention of tumor recurrence in vitro (59, 62). In
addition, immune-deprived mice, carrying rabbit CE-expressing
2184 Review of CPT-11 Pharmacokinetics
Rh30 cells, were more sensitive to CPT-11 than human CE-
expressing cells or control cells. No recurrent tumors occurred
in the rabbit-enzyme group, in contrast to 29 and 100% recur-
rence in the two other groups, respectively (59). The clinical
utility of this approach is currently under further investigation.
UGT-mediated Biotransformation. SN-38 itself is fur-
ther metabolized in human liver by UGT1A1 to an inactive
compound, SN-38G (63–65). The lactone functionality of SN-
38G could also be hydrolyzed after a pH-dependent equilibrium
(65). Mostly, the plasma concentrations of SN-38G are related
to SN-38 plasma concentrations, with peak values at 1.2 h
(range, 15 min to 4.5 h) after the end of infusion (31, 43, 66).
SN-38G concentrations increase linearly with the administered
CPT-11 dose, suggesting that hepatic glucuronidation is not
saturated in the dose ranges studied (up to 600 mg/m2; Refs. 36,
42). The AUC of SN-38G is 7-fold higher than that of SN-38,
suggesting extensive glucuronidation of SN-38 into SN-38G
(32, 66), with high interpatient variability (41).
Considerable variation in the conversion of SN-38 into
SN-38G in human liver cells has also been noticed in vitro (63).
This may be attributable to different enzyme activities of the
various UGT isoforms. Two distinct gene families of UGT
enzymes exist, UGT1 and UGT2, which are both being subclas-
sified into several isoforms. Results obtained from transfection
studied have shown that isoform UGT1A1 is primarily respon-
sible for the SN-38 conversion (63), although it was shown more
recently that isoform 1A7 is 21-fold more efficient at physi-
ological pH than UGT1A1 (67).
A genetic polymorphism has been reported in the TATA
box sequences of UGT1A1 (68). Normally, the box contains
(TA)6TAA in its promoter region, and sometimes a box contains
an extra TA repeat (68, 69). An extra TA repeat in the TATA
box has been associated with Gilbert’s syndrome (70). The
metabolic ratio (SN-38:SN-38G) for these patients is signifi-
cantly higher compared with the common genotype, suggesting
less SN-38 glucuronidation capacity (69). In addition, it has
been reported that in patients with the Crigler-Najjar type I
syndrome, UGT1 activity is totally lacking (63, 71, 72). As a
result, SN-38 cannot be inactivated adequately into SN-38G,
and therefore patients with these disorders are at increased risk
for severe CPT-11-induced toxicity (63). On the basis of the
relative importance of the systemic glucuronidation and the
existence of genetic polymorphism, it has been proposed that
UGT1A1 genotyping might be an approach to individualize
CPT-11 treatment schedules (68, 73).
A significant correlation was observed recently between
SN-38 glucuronidation rates and bilirubin glucuronidation by
human liver microsomes (63). Interestingly, UGT1A1 is the
isozyme that also conjugates bilirubin (72). Also for bilirubin
glucuronidation, an inverse correlation between glucuronidation
rate and number of TA repeats has been reported (68–70). It has
been shown subsequently that baseline values of unconjugated
bilirubin correlate significantly with both neutropenia and the
AUCs of CPT-11 and SN-38, and this relationship might thus be
useful in individual dose prescription or adaptation (72). No
relationship has been observed between the glucuronidation of
SN-38 and that of para-nitrophenol, which is glucuronidated by
several UGTs, including UGT1A1 (63). An intriguing observa-
tion has been that valproic acid, an inhibitor of glucuronidation,
given 5 min before CPT-11 in rats, caused 99% inhibition in
SN-38G formation (74), resulting in a mean increase in SN-38
AUC of 270%. Pretreatment with phenobarbital, an inducer of
UGT, resulted in a 72% enhancement in the AUC of SN-38G,
with a concomitant reduction in the AUCs of CPT-11 and
SN-38 of 31 and 59%, respectively (74). These findings are
consistent with data indicating that a patient with Gilbert’s
syndrome could be treated successfully with simultaneous ad-
ministration of CPT-11 and phenobarbital (31). CPT-11 and
SN-38 were formed in concentrations comparable with those
achieved in normal patients, although the AUC of SN-38G
appeared to be substantially altered (31).
In human lung cancer cell lines, the role of SN-38 glucu-
ronidation in cytotoxicity profiles has been studied extensively
(75). PC-7/CPT cell lines showed an increased glucuronidation
in comparison with normal PC-7 cells, and when UGT activity
was inhibited, the cells became more sensitive to SN-38. Thus,
an up-regulation of the UGT activity may lead to SN-38 resist-
ance in the tumor (75). BCRP or mitoxantrone-resistance half-
transporter (MXR) expression was also found to result in 400-
1000-fold resistance to SN-38 as compared with parental cell
lines (76). Because MXR cells were highly capable to resist
drugs that are susceptible to glucuronidation, UGT activity in
resistant and normal cell lines were compared. In resistant cells,
higher SN-38G levels were seen than in normal cells. Thus, in
cancer cells glucuronidation might contribute to drug resistance,
but the lack of high UGT levels in resistant MXR cells suggests
that BCRP alone is sufficient to induce drug resistance patterns
(76).
CYP3A-mediated Biotransformation. Recently, other
quantitatively important metabolites of CPT-11 have been iden-
tified, the formation of which is dependent of CYP3A. Of these,
APC is a major metabolite detectable in plasma and is formed
by a CYP3A-mediated oxidation of the distal piperidine group
at C10 of CPT-11 (77–79). NPC is also formed through this
pathway, by cleavage of the distal piperidino group of CPT-11
(77, 79–82). APC peaks at 2 h after the end of infusion, and
AUC values increase linearly with increasing CPT-11 dose,
despite important interpatient variation (36). At equimolar con-
centrations (as compared with CPT-11), APC did not inhibit the
conversion of CPT-11 into SN-38 (83).
Similar to CPT-11, APC shows little cytotoxic activity,
although it has some inhibitory effect on acetylcholinesterase,
an enzyme involved with the acute cholinergic syndrome ob-
served directly following CPT-11 administration (83). It is
likely that APC does not contribute directly to the total activity
and toxicity after CPT-11 administration in vivo, because it
shows minor antitumor activity in vitro compared with SN-38
and less toxicity compared with CPT-11. NPC is also a poor
inhibitor of cell growth and a poor inducer of topoisomerase
I-DNA cleavable complexes, with less antitumor activity in cell
lines than CPT-11 (80, 84). In addition, formation of APC and
NPC is unlikely to take place in human (colorectal) tumors,
where CYP3A levels are generally very low (85). It is of
particular interest, though, that human liver microsomes and
human liver CE are able to hydrolyze NPC into SN-38 though
still to a lesser extent than CPT-11 (80, 84), whereas for APC
this conversion has not been demonstrated conclusively (80,
86). Nevertheless, patients with high AUCs of SN-38, also had
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high AUCs of CPT-11 and APC, suggesting that some degree of
correlation might be present (36). In addition, NPC cannot be
formed from APC, in contrast to a formerly suggested conver-
sion (81, 84).
The recognition that CPT-11 is a CYP3A substrate is an
important finding, because it makes this agent subject to a host
of enzyme-mediated drug interactions, even with commonly
prescribed comedication (81, 87). For example, the prototypical
CYP3A inhibitors, ketoconazole and troleandomycine, inhibit
the conversion of CPT-11 into APC and NPC almost completely
(77–79, 81). In addition, both loperamide and racecadotril in-
hibit APC and NPC formation by 50%, whereas ondansetron
inhibits these formations by 25 and 75%, respectively (78, 81).
APC and NPC formation correlated significantly with testoster-
one 6 hydroxylation, which is also mediated by CYP3A (78,
81). It has been shown recently that the subtype CYP3A4 is the
main isozyme involved in formation of both APC and NPC (79,
82), although it was suggested previously that cytosolic alde-
hyde dehydrogenase might also be involved in APC formation
(81). CYP3A5 also showed catalytic activity, but neither APC
nor NPC was formed in its presence (79, 82). Instead, a new
(unidentified) metabolite was found (79, 82). Because this en-
zyme is expressed in only 25–30% of adult livers, this might
explain some of the interpatient variability in CPT-11 metabo-
lism (82). Preliminary evidence has also been generated
indicating that SN-38 might be metabolized by CYP3A4,
although the clinical implications of this finding have not yet
been evaluated.
-Glucuronidase-mediated Biotransformation. When
SN-38G is excreted in bile and intestines, several bacteria in-
cluding Escherichia coli, Bacteroides species, and Clostridium
perfringens can convert this compound back to the active me-
tabolite SN-38 by producing the enzyme -glucuronidase (88–
90). Various studies have described (microflora-derived) -
glucuronidase activity in nonhuman (91–94) and human
intestines (95–97). In rats and athymic mice, within 1 h after the
end of infusion, acute diarrheal symptoms with impaired water
absorption and increased prostaglandin E2 levels have been
found (92, 93). Histopathological changes in the descending
colon, cecum, and ileum were observed after the daily admin-
istration of CPT-11 (91–93). Recently, these mucosal abnormal-
ities were confirmed in human colon (97). A good correlation
between this histological damage and -glucuronidase activity
in the intestinal lumen has been noticed, whereas a poor corre-
lation was observed with CE activity (91). The lesser damage
found in small intestines compared with damage in the colon
could be explained by a lower exposure of this tissue to SN-38.
This may be attributable to a smaller amount of -glucuronidase
in the lumen of small intestines (94).
Because many drugs could affect the functioning of the
intestinal bacteria, comedication may influence the chemother-
apeutic treatment of patients with CPT-11 (98). Because bacte-
ria producing -glucuronidase activity will be killed by antibi-
otics, it is anticipated that this will lead to a reduction in acute
and delayed diarrhea and cecal damage (91). It has been dem-
onstrated that antibiotics had no effects on the plasma concen-
trations of CPT-11, SN-38, or SN-38G in mice (penicillin/
streptomycin; Ref. 94) and in humans (neomycin; Ref. 99). This
combined treatment also resulted in reduced SN-38 concentra-
tions in the intestinal contents with concomitantly increased
SN-38G levels (94, 99). A potential approach for modulating
CPT-11-induced intestinal toxicity may therefore be to reduce
bacterial -glucuronidase-mediated deconjugation of SN-38 and
subsequent mucosal destruction. A clinical trial to evaluate the
toxicological consequences of pretreatment with neomycin be-
fore the administration of CPT-11 is in progress at our institute.
Excretion
Several studies have examined the excretion of CPT-11 in
bile, feces, and urine in animals and humans. In humans, only
52% of the given dose has been recovered using nonradiometric
HPLC methods (32, 100), whereas in a recent radiometric study
quantitative recovery (95.8  2.7% of radioactivity) was ob-
tained (20). CPT-11 and its three most common metabolites
(SN-38, SN-38G, and APC) were responsible for almost all
(93%) detected material (20).
Urinary Elimination. In urine, CPT-11, APC, and SN-
38G are the main compounds detected within 24 h after CPT-11
administration (20, 32), with CPT-11 accounting for about 10–
22% of the administered dose and SN-38 contributing only
0.18–0.43% (20, 22, 25, 31, 66, 100). Consistent with the
highly polar nature of the glucuronic acid group and increased
aqueous solubility, SN-38G may be excreted rapidly by the
kidneys (32). The cumulative excretion of APC and NPC was
very low, amounting to1% of the dose (32). This suggests that
the bulk of CPT-11 and its metabolites is excreted during the
first 24 h after infusion, whereas assessing urinary recovery of
radiolabeled CPT-11 over 196 h also showed that the excretion
was almost complete within 48 h (Table 1; Ref. 20). Similar
findings were obtained with daily administration schedules
of CPT-11, indicating unchanged urinary excretion profiles
(26, 29).
Biliary Secretion. In a few patients, CPT-11 and SN-38
concentrations in bile have been measured (20, 24, 25, 100).
CPT-11, SN-38, and SN-38G biliary secretion varies between
approximately 3–22, 0.1–0.9, and 0.6–1.1%, respectively (100).
NPC was also detected in bile at very low concentrations (80).
In a female patient, carrying a biliary T-tube and receiving
radiolabeled CPT-11, 30.1% of the administered dose was re-
covered in bile as radioactive compounds (20).
In rats, a cMOAT located on the bile canalicular membrane
was shown to be responsible for the transport of CPT-11 car-
Table 1 Cumulative urinary and fecal excretion of CPT-11 and
metabolites
Compound Urine Feces Total
CPT-11 22.4  5.50 32.3  4.47 54.7
SN-38G 3.02  0.77 0.27  0.17 3.29
SN-38 0.43  0.12 8.24  2.51 8.67
APC 2.23  1.53 8.29  2.95 10.5
NPC 0.14  0.08 1.36  0.94 1.50
Total compounds 30.2  6.60 62.0  7.60 92.2
Not extracted 1.25  1.55 9.86  3.77 11.1
Parent drug and metabolite abundance are expressed as percentages
of administered dose and were determined by quantitative radiometric
high-performance liquid chromatography. Data were obtained from
Slatter et al. (20).
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boxylate, SN-38 carboxylate, and both SN-38G carboxylate and
lactone (101). For CPT-11 carboxylate, cMOAT appeared to be
a low-affinity transporter, whereas a high-affinity transporter is
still unknown (102). For SN-38G lactone and carboxylate,
cMOAT is the high-affinity transporter, whereas a low-affinity
transporter most likely also exists, presumably P-gp. It has also
been found that cMOAT transports SN-38G carboxylate more
efficiently than its lactone form (102). In humans, the same
transport mechanisms by cMOAT of CPT-11 carboxylate,
SN-38 carboxylate, and SN-38G were found as in rats (Fig. 3;
Ref. 103).
Cyclosporin A, an inhibitor of the biliary secretion (104),
and a known substrate and inhibitor of P-gp (105), significantly
increased plasma concentrations of CPT-11, SN-38, and SN-
38G in rats (104). At a cyclosporin A dose of 60 mg/kg, the
AUCs of CPT-11, SN-38, and SN-38G increased 2–4-fold. This
is most likely the result of reduced renal and nonrenal clearance,
which simultaneously was reduced by 55 and 81%, respectively.
Simultaneously, the terminal disposition half-lives of CPT-11
and its metabolites were substantially prolonged. The conver-
sion of CPT-11 into SN-38 was not altered, but the glucuronida-
tion of SN-38 decreased in comparison to CPT-11 infusion
without cyclosporin A (104). In view of these results, it has been
suggested that P-gp is one of the high-affinity transporters of
CPT-11 carboxylate (106). However, similar to P-gp, cMOAT
function may also be inhibited by cyclosporin A or other sub-
strates and modulators (106). Therefore, inhibition has been
studied at various concentrations of CPT-11. Because the high-
affinity component is most active at substrate concentrations of
5 M and cMOAT is most active at 250 M, inhibitors of P-gp
and cMOAT were compared at these concentrations. It appeared
that P-gp substrates or modulators such as verapamil, PSC-833
(valspodar), or cyclosporin A inhibited the uptake of CPT-11
carboxylate most at concentrations of 5 M. This suggests that
P-gp might be the high-affinity component in CPT-11 carbox-
ylate transport (106).
As an adverse effect, cyclosporin A also inhibits bilirubin
excretion, and this may lead to hyperbilirubinemia (104). In the
human Dubin-Johnson syndrome, chronic hyperbilirubinemia is
seen as a result of a mutation in the cMOAT gene (107), and
variability in the expression of this protein might play a role in
the variability in experienced toxicity during CPT-11 treatment
(103).
Fecal Excretion. In a mass balance study using radiola-
beled CPT-11, fecal excretion was the major route of drug
elimination, with 63.7% of the administered drug recovered
(20). The unexpectedly high SN-38 concentrations and rela-
tively low SN-38G concentrations in fecal specimens are sug-
gestive for substantial -glucuronidase activity in human intes-
tinal contents, and consequently, the SN-38:SN-38G ratio was
relatively high in all patients (20, 32). SN-38, APC, and NPC
are mainly excreted in feces, 2.5 and 1.7% for SN-38 and NPC,
respectively (32).
Considerations of Schedule and Route
of Administration
Despite all kinds of dosing schedules, the total CPT-11
dose that can be tolerated in any time period is the same
(23–25). Prolonged infusion times might theoretically improve
the efficacy of CPT-11, because cytotoxicity of topoisomerase I
inhibitors is S-phase specific (10), although the relevance of this
principle for CPT-11, given the prolonged terminal disposition
half-life of SN-38, is unclear. From xenograft models, it was
known that low-dose protracted schedules of CPT-11 adminis-
tration were more effective and less toxic than the usual higher
dose, short infusion periods (108, 109). Chronic low-dose ex-
posure of CPT-11 in patients has been studied recently (29, 39,
45, 110, 111) and revealed that the AUC ratios of lactone to total
drug for CPT-11 and SN-38 were in the same range as for the
shorter infusion periods (29). The maximal and recommended
tolerated doses in these studies, 10–30 mg/m2/day, are much
lower for the prolonged infusions than for the shorter durations.
Surprisingly, the SN-38 AUC levels reached similar values as
compared with those of the shorter infusion periods, presumably
reflecting saturation of enzymatic biotransformation with the
latter schedules (29, 39, 45, 110).
Oral Administration. Clearly, the availability of a suit-
able oral formulation of CPT-11 would allow more convenient
use of prolonged dosing schedules. When human liver and
intestine S9 fractions were incubated with CPT-11, the agent
was mostly hydrolyzed into SN-38 by liver, duodenal, jejunal,
and ileal fractions and less by colon and rectal fractions (91,
112). Because it has been discovered that CEs are widely
expressed in the human liver and gastrointestinal tract, it may be
possible to effectively administer CPT-11 p.o. (112, 113), with
the knowledge that substantial presystemic metabolism could
take place. The low pH value of the stomach may be favorable
for the retention of CPT-11 in its lactone form (113).
Oral administration of CPT-11 in mice resulted in peak
concentrations of CPT-11 and SN-38 in plasma within 1 h after
administration (114, 115), and the bioavailability of CPT-11
increased with increasing dose and amounted to 10–20% (115).
In contrast, and of concern, the SN-38 AUC after oral admin-
istration did not correlate linearly with the dose, and in fact even
decreased with increasing CPT-11 dose. It has been suggested
that saturation of CE might cause this nonlinear correlation
Fig. 3 Primary active transport systems for CPT-11 and its metabolites
in the bile canalicular membrane of humans indicating the hypothesis
for the mechanism of toxicity caused by i.v. administration of CPT-11
[modified from Sugiyama et al. (105)]. 1, carboxylesterase-mediated
conversion; 2, CYP3A-mediated conversion; 3, UGT1A-mediated con-
version; 4, -glucuronidase-mediated conversion.
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(115), but the high levels of CE expressed in human intestinal
tissues do not render this suggestion very likely (113). The
higher SN-38 total:CPT-11 total ratios, compared with i.v. ad-
ministration, suggest a presystemic CPT-11 conversion (116).
Lactone versus carboxylate CPT-11 ratio was comparable with
i.v. infusions, but the SN-38 ratio was much higher (113),
suggesting a longer persistence of SN-38 lactone when it is
given p.o. When CPT-11 was given orally to nude mice bearing
human tumor xenografts, the agent retained its cytotoxic prop-
erties (53). Furthermore, in early clinical trials initial antitumor
activity has been observed (113), suggesting that oral CPT-11
might be an attractive therapeutic option for the treatment of
several human malignancies.
The uptake rates of [14C]CPT-11 and [14C]SN-38 from
hamster intestinal epithelial cells and human colon carcinoma
HT29 cells were recently published, providing important insight
on the absorption characteristics of these agents (117). The
lactone forms of CPT-11 and SN-38 were transported mainly by
a passive diffusion, whereas the carboxylate forms were ab-
sorbed as a result of an active transport mechanism. Both
compounds were transported significantly more in their lactone
form, and the uptake rates showed a clear pH dependency,
because the uptake decreased to 68% when the pH values were
higher than 6.8. Lower SN-38 uptake rates also correlated with
lower cytotoxicity (117). It was suggested that raising pH values
in human intestines might decrease the reabsorption of the drug
and as a result it will lower the intestinal side effects (117). The
clinical utility of this concept is currently under further inves-
tigation. Clearly, demonstration of unaltered pharmacokinetics
of SN-38 in the presence of intestinal alkalization is of crucial
importance. Thus, although these investigators have shown that
this concept can reduce CPT-11-induced intestinal toxicity, this
may be a pyrrhic victory if a simultaneously altered metabolic
clearance (by way of a decreased enterohepatic recirculation of
SN-38) results in reduced antitumor activity.
i.p. Administration. i.p. administration of CPT-11 has
also been studied recently and may have some potential advan-
tages over the i.v. route. It appeared that the therapy was more
effective and less toxic in mice bearing C26 colon cancers (118).
In mice bearing P388 leukemia ascites, substantially elevated
peritoneal AUCs of CPT-11 and SN-38 were found, whereas the
achieved plasma levels were comparable with those after i.v.
dosing (118). If the i.p. administration of CPT-11 does not prove
to have major local toxicities, this administration pathway might
be an asset for the adjuvant therapy of colorectal cancer.
Pharmacokinetic-Pharmacodynamic Relationships
Relationships between pharmacokinetic parameters and
CPT-11-induced side effects have been studied extensively. For
abdominal cramps, nausea, vomiting, and anorexia, no correla-
tion with any parameter has been found (23). For myelosup-
pression and diarrhea in relation to the AUCs of CPT-11 and
SN-38, respectively, the findings are highly variable, and final
conclusions cannot yet be drawn (Table 2; Refs. 21, 29, 45).
The product of the plasma AUC ratio of SN-38:SN-38G
and the plasma CPT-11 AUC (i.e., the biliary index) may be an
important kinetic variable because it is thought to be correlated
with SN-38 bile concentrations (66). Patients with high biliary
indices, suggestive of high SN-38 biliary concentrations, in
some studies experienced more severe diarrhea (grades 3 and 4
on the National Cancer Institute-Common Toxicity Criteria
scale) than those with low biliary indices (31, 66), but this could
not be confirmed in other studies (21, 119, 120). It has been
hypothesized that consideration of interindividual differences in
fecal -glucuronidase activity would likely assist in a more
accurate prediction of CPT-11-induced intestinal side effects
and may provide a basis to modulate the experienced toxicity
(32).
Evaluation of Drug Interactions
Drug interactions may arise as a result of altered pharma-
codynamics or pharmacokinetics of the drugs involved. In the
case of pharmacokinetic interactions, this is usually attributable
to modification of tissue disposition and metabolism of the
drugs. These phenomena are of particular importance in cancer
chemotherapy when cytotoxic agents are used, because of the
increased risks of severe toxicity. Most of the data available
currently to evaluate potential drug interactions with CPT-11
come from clinical trials of CPT-11 given in combination with
one or more other anticancer agents (Table 3). Although in
several cases only limited information is available, some (pre-
liminary) conclusions can be drawn.
Pharmacokinetic interaction studies have been performed
with cisplatin either given alone or in combination with vin-
desine (121, 122) or ifosfamide (123), and indicated unaltered
disposition profiles of both CPT-11 and its metabolites at any
dose level or sequence tested (124–126). Likewise, the pharma-
cokinetics of carboplatin were not influenced by CPT-11, al-
though in one study, the AUC of both CPT-11 and SN-38 was
lower than expected, suggesting increased clearance of CPT-11
when given together with carboplatin (127, 128). The basis for
this apparent change in pharmacokinetic behavior is unknown,
although an effect on CYP3A expression attributable to prior
exposure to carboplatin cannot be excluded (129).
In a Japanese study, altered pharmacokinetics were also
found when 5-fluorouracil was administered immediately after
CPT-11 infusion (130). Compared with an earlier CPT-11
monotherapy study conducted by the same group, the AUC of
CPT-11 substantially increased whereas the AUC of SN-38
decreased. An inhibition of CE by 5-FU was suggested to
explain these unexpected results (130). Other studies did not
find altered pharmacokinetics for this combination therapy or
eventually with the further addition of leucovorin (folinic acid;
Table 2 Correlation between toxicities and the AUCs of CPT-11 and
SN-38
Observed toxicity CPT-11 AUC SN-38 AUC Refs.
Neutropenia No No 26, 29, 40, 45
No Yes 23, 39
Yes Yes 21, 22, 25, 27
Diarrhea No No 21, 23, 29, 45
No Yes 40
Yes No 26, 39
Yes Yes 22, 25, 27
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Refs. 131–134). The conclusion from the Japanese study has
been criticized in view of the large interpatient variation and
noncomparable patient populations (134).
Although no comparative pharmacokinetic data are avail-
able, it has also been suggested that an interaction or sequence-
dependent effect is present for the combination of CPT-11 and
docetaxel. Because both drugs are metabolized by CYP3A,
competition might occur when these drugs are given sequen-
tially, and as a result, the clearance of docetaxel might be
decreased (135). A significant pharmacokinetic interaction has
been observed between CPT-11 and paclitaxel, which is char-
acterized by increased plasma levels of both CPT-11 and SN-38
(136). Similar reactions have also been reported in rats (137)
and Cremophor EL, the vehicle used for paclitaxel formulation
seems to play a major role (104). This type of interaction
appears to be related to micellar encapsulation of certain agents
in this vehicle and has also been demonstrated to occur with
paclitaxel itself and anthracyclines (138). In any event, because
this interaction occurs during the terminal disposition phase of
CPT-11, in currently applied dosing schedules the interaction is
likely of only minor importance. The combination of weekly
administration of CPT-11 with a fixed dose of paclitaxel (75
mg/m2) indicated that the sequence of drug administration did
not affect elimination of CPT-11 (139). There was also no
sequence-dependent, chemotherapy-related toxicity. To date, no
other cytotoxic drug has been shown to affect the pharmacoki-
netics of CPT-11 or was affected itself by CPT-11.
Anticonvulsants, phenytoin and phenobarbital in particular,
are known to induce several metabolic pathways relevant to
xenobiotics. CYP3A4, in particular, has increased expression
when patients are treated with these compounds. Indeed, a
recent study in patients with recurrent or progressive malignant
glioma receiving CPT-11 and phenytoin indicated that AUCs of
CPT-11, SN-38, and SN-38G were approximately 40, 25, and
25%, respectively, of those determined previously in patients
with metastatic colorectal cancer not receiving antiepileptics
(140). Similarly, enzyme-inducing anticonvulsants significantly
lowered systemic exposure to CPT-11 and SN-38 in children
with newly diagnosed high-grade glioma (141). This interaction
is of major importance because it suggests that anticonvulsants
thereby largely reduce the potential antitumor effects of CPT-
11. In addition to modulation of CYP3A4, another possible
explanation for the interaction is the induction of membrane
transporters that enhance drug excretion (142).
Table 4 Factors contributing to variability in response to CPT-11
Parameter Source of variability Example(s)
Dose selection Patient’s condition Performance status
Host sensitivity Previous treatments
Systemic exposure Concomitant drugs Cyclosporin A (P-glycoprotein inhibitor)




Pharmacogenetics Gilbert’s syndrome (UGT1A1 mutation)
Crigler-Najjar type 1 syndrome (UGT1A1 deficiency)
Dubin-Johnsson syndrome (cMOAT mutation)
Altered organ functions Hepatic dysfunction
Active site levels Resistance mechanisms P-glycoprotein
BCRP
Topoisomerase I mutations
CYP3A4 and/or UGT1A1 overexpression
Table 3 Evaluation of pharmacokinetic interactions between CPT-11 and anticancer agents
Combination
drug(s) Dose (CPT-11) (mg/m2) Kinetic alterations Refs.
Carboplatin 5a (60) AUCCPT-11 2; AUCSN-38 2 127, 128
Cisplatin 80 (260) None 32, 119, 124, 125
Cisplatin/Vindesine 100/3.0 (37.5) None 120, 121
Cisplatin/Ifosfamide 70/1.5 (60) None 123
Docetaxel 75 (200) None 135
70 (250) None 149
50 (60) None 150
Etoposide 80 (80) None 30
5-Fluorouracil 500 (125) AUCCPT-11 1; AUCSN-38 2 130
2600 (80) None 131, 132, 134
Oxaliplatin 85 (200) None 148
Paclitaxel 175 (150) AUCCPT-11 1; AUCSN-38 1 136, 137
75 (50) None 139
Raltitrexed 3.0 (350) None 151
a Target AUC in mgmin/ml.
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Conclusions and Perspectives
CPT-11, because of its broad spectrum of antitumor activ-
ity, is clearly one of the most important new anticancer drugs
developed in the last few decades. The clinical pharmacokinetic
behavior of CPT-11 has been explored extensively in recent
years, and the generated information has been of fundamental
importance in our understanding of the clinical effects of this
agent (Table 4). In addition, a wealth of information has become
available that has yielded valuable insight into the mechanism of
action, the mechanisms of tumor resistance, toxicities, and con-
siderations of dosage and schedule and route of drug adminis-
tration. Many of these studies have been made possible by the
development of selective analytical methodologies to specifi-
cally monitor the parent drug and individual metabolites, with
sufficient sensitivity to detect the compounds at levels achieved
after therapeutic dosing. However, only through further inves-
tigations that may allow better definition of the biochemistry
and pharmacokinetics of CPT-11 can the rational optimization
of therapy involving this agent be achieved. This need has
become even more important in light of the current clinical use
of CPT-11 in combination with other antineoplastic drugs or
agents specifically administered to modify CPT-11-induced tox-
icity profiles (143). In this respect, the use of mathematical
models to predict systemic exposure measures for CPT-11 and
its metabolites by application of limited-sampling strategies (38,
41, 144–147), coupled with continued investigations into the
role of individual enzyme expression levels and detection of
enzyme polymorphism, will allow more rational and selective
chemotherapy with this agent.
References
1. Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail,
A. T., and Sim, G. A. Plant antitumor agents. I. The isolation and
structure of camptothecine, a novel alkaloidal leukemia and tumor
inhibitor from Camptotheca acuminata. J. Am. Chem. Soc., 88: 3888–
3890, 1966.
2. Muggia, F. M., Creaven, P. J., Hansen, H. H., Cohen, M. H., and
Selawry, O. S. Phase I clinical trial of weekly and daily treatment with
camptothecin (NSC-100880): correlation with preclinical studies. Can-
cer Chemother. Rep., 56: 515–521, 1972.
3. Moertel, C. G., Schutt, A. J., Reitemeier, R. J., and Hahn, R. G. Phase
II study of camptothecin (NSC-100880) in the treatment of advanced
gastrointestinal cancer. Cancer Chemother. Rep., 56: 95–101, 1972.
4. Schaeppi, U., Fleischman, R. W., and Cooney, D. A. Toxicity of
camptothecin (NSC-100880). Cancer Chemother. Rep., 5: 25–36, 1974.
5. Creemers, G. J., Lund, B., and Verweij, J. Topoisomerase I inhibi-
tors. Topotecan and irinotecan. Cancer Treat. Rev., 20: 73–96, 1994.
6. Rajkumar, S. V., and Adjei, A. A. A review of the pharmacology and
clinical activity of new chemotherapeutic agents in lung cancer. Cancer
Treat. Rev., 24: 35–53, 1998.
7. Hsiang, Y-H., Hertzberg, R., Hecht, S., and Liu, L. F. Camptothecin
induces protein-linked DNA breaks via mammalian DNA topoisomer-
ase I. J. Biol. Chem., 260: 14873–14878, 1985.
8. Hsiang, Y-H., and Liu, L. F. Identification of mammalian DNA
topoisomerase I as an intracellular target of the anticancer drug camp-
tothecin. Cancer Res., 48: 1722–1726, 1988.
9. Hsiang, Y-H., Lihou, M. G., and Liu, L. F. Arrest of replication forks
by drug-stabilized topoisomerase I-DNA cleavable complexes as a
mechanism of cell killing by camptothecin. Cancer Res., 49: 5077–
5082, 1989.
10. Gerrits, C. J. H., de Jonge, M. J. A., Schellens, J. H. M., Stoter, G.,
and Verweij, J. Topoisomerase I inhibitors: the relevance of prolonged
exposure for clinical development. Br. J. Cancer, 76: 952–962, 1997.
11. O’Leary, J., and Muggia, F. M. Camptothecins: a review of their
development and schedules of administration. Eur. J. Cancer, 34: 1500–
1508, 1998.
12. Gelderblom, H. A., de Jonge, M. J. A., Sparreboom, A., and
Verweij, J. Oral topoisomerase I inhibitors in adult patients: present and
future. Investig. New Drugs, 17: 401–415, 1999.
13. Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi,
M., Yokokura, T., Sawada, S., Miyasaka, T., and Mutai, M. Antitumor
activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-campto-
thecin, a novel water-soluble derivative of camptothecin, against murine
tumors. Cancer Res., 47: 5944–5947, 1987.
14. Kingsbury, W. D., Boehm, J. C., Jakas, D. R., Holden, K. G., Hecht,
S. M., Gallagher, G., Caranfa, M. J., McCabe, F. L., Faucette, L. F., and
Johnson, R. K. Synthesis of water-soluble (aminoalkyl)camptothecin
analogues: inhibition of topoisomerase I and antitumor activity. J. Med.
Chem., 34: 98–107, 1991.
15. Pantazis, P., Harris, N., Mendoza, J., and Giovanella, B. The role of
pH and serum albumin in the metabolic conversion of 9-nitrocampto-
thecin to 9-aminocamptothecin by human hematopoietic and other cells.
Eur. J. Haematol., 55: 211–213, 1995.
16. Loos, W. J., Sparreboom, A., Verweij, J., Nooter, K., Stoter, G., and
Schellens, J. H. M. Determination of the lactone and lactone plus
carboxylate forms of 9-aminocamptothecin in human plasma by sensi-
tive high-performance liquid chromatography with fluorescence detec-
tion. J. Chromatogr. B, 694: 435–441, 1997.
17. Blaney, S., M., Takimoto, C., Murry, D. J., Kuttesch, N., McCully,
C., Cole, D. E., Godwin, K., and Balis, F. M. Plasma and cerebrospinal
fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan
(CPT-11), and SN-38 in nonhuman primates. Cancer Chemother. Phar-
macol., 41: 464–468, 1998.
18. Emerson, D. L., Besterman, J. M., Brown, H. R., Evans, M. G.,
Leitner, P. P., Luzzio, M. J., Shaffer, J. E., Sternbach, D. D., Uehling,
D., and Vuong, A. In vivo antitumor activity of two new seven-substi-
tuted water-soluble camptothecin analogues. Cancer Res., 55: 603–609,
1995.
19. Vey, N., Giles, F. J., Kantarjian, H., Smith, T. L., Beran, M., and
Jeha, S. The topoisomerase I inhibitor DX-8951f is active in a severe
combined immunodeficient mouse model of human acute myelogenous
leukemia. Clin. Cancer Res., 6: 731–736, 2000.
20. Slatter, J. G., Schaaf, L. J., Sams, J. P., Feenstra, K. L., Johnson,
M. G., Bombardt, P. A., Cathcart, K. S., Verburg, M. T., Pearson, L. K.,
Compton, L. D., Miller, L. L., Baker, D. S., Pesheck, C. V., and Lord,
R. S. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-
11) following i.v. infusion of [14C]CPT-11 in cancer patients. Drug
Metab. Dispos., 28: 423–433, 2000.
21. Canal, P., Gay, C., Dezeuze, A., Douillard, J. Y., Bugat, R., Brunet,
R., Adenis, A., Herait, P., Lokiec, F., and Mathieu-Boue, A. Pharma-
cokinetics and pharmacodynamics of irinotecan during a Phase II clin-
ical trial in colorectal cancer. J. Clin. Oncol., 14: 2688–2695, 1996.
22. Abigerges, D., Chabot, G. G., Armand, J-P., Herait, P., Gouyette,
A., and Gandia, D. Phase I and pharmacologic studies of the campto-
thecin analog irinotecan administered every 3 weeks in cancer patients.
J. Clin. Oncol., 13: 210–221, 1995.
23. Rowinsky, E. K., Grochow, L. B., Ettinger, D. S., Sartorius, S. E.,
Lubejko, B. G., Chen, T. L., Rock, M. K., and Donehower, R. C. Phase
I and pharmacological study of the novel topoisomerase I inhibitor
7-ethyl-10-[4-(1-(piperidino)-1-piperidino] carbonyloxycamptothecin
(CPT-11) administered as a ninety-minute infusion every 3 weeks.
Cancer Res., 54: 427–436, 1994.
24. Rothenberg, M. L., Kuhn, J. G., Burris, H. A., Nelson, J., Eckardt,
J. R., Tristan-Morales, M., Hilsenbeck, S. G., Weiss, G. R., Smith, L. S.,
and Rodriguez, G. I. Phase I and pharmacokinetic trial of weekly
CPT-11. J. Clin. Oncol., 11: 2194–2204, 1993.
25. de Forni, M., Bugat, R., Chabot, G. G., Culine, S., Extra, J. M.,
Gouyette, A., Madelaine, I., Marty, M. E., and Mathieu-Boue, A. Phase
2190 Review of CPT-11 Pharmacokinetics
I and pharmacokinetic study of the camptothecin derivative irinotecan,
administered on a weekly schedule in cancer patients. Cancer Res., 54:
4347–4354, 1994.
26. Catimel, G., Chabot, G. G., Guastalla, J. P., Dumortier, A., Cote, C.,
Engel, C., Gouyette, A., Mathieu-Boue, A., Mahjoubi, M., and Clavel,
M. Phase I and pharmacokinetic study of irinotecan (CPT-11) admin-
istered daily for three consecutive days every three weeks in patients
with advanced solid tumors. Ann. Oncol., 6: 133–140, 1995.
27. Sasaki, Y., Hakusui, H., Mizuno, S., Morita, M., Miya, T., Eguchi,
K., Shinkai, T., Tamura, T., Ohe, Y., and Saijo, N. A pharmacokinetic
and pharmacodynamic analysis of CPT-11 and its active metabolite
SN-38. Jpn. J. Cancer Res., 86: 101–110, 1995.
28. Pitot, H. C., Goldberg, R. M., Reid, J. M., Sloan, J. A., Skaff, P. A.,
Erlichman, C., Rubin, J., Burch, P. A., Adjei, A. A., Alberts, S. A.,
Schaaf, L. J., Elfring, G., and Miller, L. L. Phase I dose-finding and
pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a
once-every-three-week dosing schedule for patients with advanced solid
tumor malignancy. Clin. Cancer Res., 6: 2236–2244, 2000.
29. Herben, V. M. M., Schellens, J. H. M., Swart, M., Gruia, G.,
Vernillet, L., Beijnen, J. H., and ten Bokkel Huinink, W. W. Phase I and
pharmacokinetic study of irinotecan administered as a low-dose, con-
tinuous intravenous infusion over 14 days in patients with malignant
solid tumors. J. Clin. Oncol., 17: 1897–1905, 1999.
30. Masuda, N., Fukuoka, M., Kudoh, S., Matsui, K., Kusunoki, Y.,
Takada, M., Nakagawa, K., Hirashima, T., Tsukada, H., and Yana, T.
Phase I and pharmacologic study of irinotecan and etoposide with
recombinant human granulocyte colony-stimulating factor support for
advanced lung cancer. J. Clin. Oncol., 12: 1833–1841, 1994.
31. Gupta, E., Mick, R., Ramirez, J., Wang, X., Lestingi, T. M., Vokes,
E. E., and Ratain, M. J. Pharmacokinetic and pharmacodynamic evalu-
ation of the topoisomerase I inhibitor irinotecan in cancer patients.
J. Clin. Oncol., 15: 1502–1510, 1997.
32. Sparreboom, A., de Jonge, M. J. A., de Bruijn, P., Brouwer, E.,
Nooter, K., Loos, W. J., van Alphen, R. J., Mathijssen, R. H. J., Stoter,
G., and Verweij, J. Irinotecan (CPT-11) metabolism and disposition in
cancer patients. Clin. Cancer Res., 4: 2747–2754, 1998.
33. Sasaki, Y., Yoshida, Y., Sudoh, K., Hakusui, H., Fujii, H., Ohtsu,
T., Wakita, H., Igarashi, T., and Itoh, K. Pharmacological correlation
between total drug concentration and lactones of CPT-11 and SN-38 in
patients treated with CPT-11. Jpn. J. Cancer Res., 86: 111–116, 1995.
34. Rivory, L. P., Chatelut, E., Canal, P., Mathieu-Boue, A., and Rob-
ert, J. Kinetics of the in vivo interconversion of the carboxylate and
lactone forms of irinotecan and of its metabolite SN-38 in patients.
Cancer Res., 54: 6330–6333, 1994.
35. Chabot, G. G., Abigerges, D., Catimel, G., Culine, S., de Forni, M.,
Extra, J. M., Mahjoubi, M., Herait, P., Armand, J. P., and Bugat, R.
Population pharmacokinetics and pharmacodynamics of irinotecan
(CPT-11) and active metabolite SN-38 during Phase I trials. Ann.
Oncol., 6: 141–151, 1995.
36. Rivory, L. P., Haaz, M-C., Canal, P., Lokiec, F., Armand, J. P., and
Robert, J. Pharmacokinetic interrelationships of irinotecan (CPT-11)
and its three major plasma metabolites in patients enrolled in Phase I/II
trials. Clin. Cancer Res., 3: 1261–1266, 1997.
37. Loos, W. J., Verweij, J., Gelderblom, H. A., de Jonge, M. J. A.,
Brouwer, E., Dallaire, B. K., and Sparreboom, A. Role of erythrocytes
and serum proteins in the kinetic profile of total 9-amino-20(S)-camp-
tothecin in humans. Anti-Cancer Drugs, 10: 705–710, 1999.
38. Mathijssen, R. H. J., van Alphen, R. J., de Jonge, M. J. A., Verweij,
J., de Bruijn, P., Loos, W. J., Nooter, K., Vernillet, L., Stoter, G., and
Sparreboom, A. Sparse-data set analysis for irinotecan and SN-38 phar-
macokinetics in cancer patients co-treated with cisplatin. Anti-Cancer
Drugs, 10: 9–16, 1999.
39. Ohe, Y., Sasaki, Y., Shinkai, T., Eguchi, K., Tamura, T., Kojima,
A., Kunikane, H., Okamoto, H., Karato, A., and Ohmatsu, H. Phase I
study and pharmacokinetics of CPT-11 with 5-day continuous infusion.
J. Natl. Cancer Inst. (Bethesda), 84: 972–973, 1992.
40. Rothenberg, M. L., Eckardt, J. R., Kuhn, J. G., Burris, H. A.,
Nelson, J., Hilsenbeck, S. G., Rodriguez, G. I., Thurman, A. M., Smith,
L. S., Eckhardt, S. G., Weiss, G. R., Elfring, G. L., Rinaldi, D. A.,
Schaaf, L. J., and Von Hoff, D. D. Phase II trial of irinotecan in patients
with progressive or rapidly recurrent colorectal cancer. J. Clin. Oncol.,
14: 1128–1135, 1996.
41. Mick, R., Gupta, E., Vokes, E. E., and Ratain, M. J. Limited-
sampling models for irinotecan pharmacokinetics-pharmacodynamics:
prediction of biliary index and intestinal toxicity. J. Clin. Oncol., 14:
2012–2019, 1996.
42. Rothenberg, M. L., Kuhn, J. G., Schaaf, L. J., Eckhardt, S. G.,
Villalona-Calero, M. A., Petit, R. G., Miller, L. L., Elfring, G. L.,
Murphy, T. C., and Von Hoff, D. D. Phase I and pharmacokinetic study
of intravenous irinotecan (CPT-11) administered once every 2 weeks
	/
 G-CSF. Ann. Oncol., 10: 63, 1998.
43. Kehrer, D. F. S., Yamamoto, W., Verweij, J., de Jonge, M. J. A., de
Bruijn, P., and Sparreboom, A. Factors involved in prolongation of the
terminal disposition phase of SN-38: clinical and experimental studies.
Clin. Cancer Res., 6: 3451–3458, 2000.
44. Combes, O., Barre´, J., Duche´, J-C., Vernillet, L., Archimbaud, Y.,
Marietta, M. P., Tillement, J. P., and Urien, S. In vitro binding and
partitioning of irinotecan (CPT-11) and its metabolite, SN-38, in human
blood. Investig. New Drugs, 18: 1–5, 2000.
45. Ma, M. K., Zamboni, W. C., Radomski, K. M., Furman, W. L.,
Santana, V. M., Houghton, P. J., Hanna, S. K., Smith, A. K., and
Stewart, C. F. Pharmacokinetics of irinotecan and its metabolites SN-38
and APC in children with recurrent solid tumors after protracted low-
dose irinotecan. Clin. Cancer Res., 6: 813–819, 2000.
46. Burke, T. G., and Mi, Z. H. The structural basis of camptothecin
interactions with human serum albumin: impact on drug stability.
J. Med. Chem., 37: 40–46, 1994.
47. Burke, T. G., Munshi, C. B., Mi, Z. H., and Jiang, Y. The important
role of albumin in determining the relative human blood stabilities of the
camptothecin anticancer drugs. J. Pharm. Sci., 84: 518–519, 1995.
48. Slatter, J. G., Su, P., Sams, J. P., Schaaf, L. J., and Wienkers, L. C.
Bioactivation of the anticancer agent CPT-11 to SN-38 by human
hepatic microsomal carboxylesterases and the in vitro assessment of
potential drug interactions. Drug Metab. Dispos., 25: 1157–1164, 1997.
49. Humerickhouse, R., Lohrbach, K., Li, L., Bosron, W. F., and Dolan,
M. E. Characterization of CPT-11 hydrolysis by human liver carb-
oxylesterase isoforms hCE-1 and hCE-2. Cancer Res., 60: 1189–
1192, 2000.
50. Wierdl, M., Morton, C. L., Danks, M. K., and Potter, P. M. Isolation
and characterization of a cDNA encoding a horse liver butyrylcholines-
terase: evidence for CPT-11 drug activation. Biochem. Pharmacol., 59:
773–781, 2000.
51. Morton, C. L., Wadkins, R. M., Danks, M. K., and Potter, P. M. The
anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase
but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res.,
59: 1458–1463, 1999.
52. Haaz, M-C., Rivory, L. P., Riche´, C., and Robert, J. The transfor-
mation of irinotecan (CPT-11) to its active metabolite SN-38 by human
liver microsomes. Naunyn Schmiedebergs Arch. Pharmacol., 356: 257–
262, 1997.
53. Kawato, Y., Furuta, T., Aonuma, M., Yasuoka, M., Yokokura, T.,
and Matsumoto, K. Antitumor activity of a camptothecin derivative,
CPT-11, against human tumor xenografts in nude mice. Cancer Che-
mother. Pharmacol., 28: 192–198, 1991.
54. Takaoka, K., Ohtsuka, K., and Jin, M. Conversion of CPT-11 to its
active form SN-38, by carboxylesterase of non-small cell lung cancer.
Proc. Am. Soc. Clin. Oncol., 16: 252, 1997.
55. van Ark-Otte, J., Kedde, M. A., van der Vijgh, W. J. F., Dingemans,
A. M., Jansen, W. J., Pinedo, H. M., Boven, E., and Giaccone, G.
Determinants of CPT-11 and SN-38 activities in human lung cancer
cells. Br. J. Cancer, 77: 2171–2176, 1998.
56. Guichard, S., Terret, C., Hennebelle, I., Lochon, I., Chevreau, P.,
Fretigny, E., Selves, J., Chatelut, E., Bugat, R., and Canal, P. CPT-11
converting carboxylesterase and topoisomerase I activities in tumour
and normal colon and liver tissues. Br. J. Cancer, 80: 364–370, 1999.
2191Clinical Cancer Research
57. Kojima, A., Hackett, N. R., Ohwada, A., and Crystal, R. G. In vivo
human carboxylesterase cDNA gene transfer to activate the prodrug
CPT-11 for local treatment of solid tumors. J. Clin. Investig., 101:
1789–1796, 1998.
58. Kojima, A., Hackett, N. R., and Crystal, R. G. Reversal of CPT-11
resistance of lung cancer cells by adenovirus-mediated gene transfer of
the human carboxylesterase cDNA. Cancer Res., 58: 4368–4374, 1998.
59. Danks, M. K., Morton, C. L., Krull, E. J., Cheshire, P. J., Richmond,
L. B., Naeve, C. W., Pawlik, C. A., Houghton, P. J., and Potter, P. M.
Comparison of activation of CPT-11 by rabbit and human carboxyles-
terases for use in enzyme/prodrug therapy. Clin. Cancer Res., 5: 917–
924, 1999.
60. Satoh, T., Hosokawa, M., Atsumi, R., Suzuki, W., Hakusui, H., and
Nagai, E. Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-
1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by car-
boxylesterase. Biol. Pharm. Bull., 17: 662–664, 1994.
61. Inaba, M., Ohnishi, Y., Ishii, H., Tanioka, Y., Yoshida, Y., Sudoh,
K., Hakusui, H., Mizuno, N., Ito, K., and Sugiyama, Y. Pharmacoki-
netics of CPT-11 in rhesus monkeys. Cancer Chemother. Pharmacol.,
41: 103–108, 1998.
62. Danks, M. K., Morton, C. L., Pawlik, C. A., and Potter, P. M.
Overexpression of a rabbit liver carboxylesterase sensitizes human
tumor cells to CPT-11. Cancer Res., 58: 20–22, 1998.
63. Iyer, L., King, C. D., Whitington, P. F., Green, M. D., Roy, S. K.,
Tephly, T. R., Coffman, B. L., and Ratain, M. J. Genetic predisposition
to the metabolism of irinotecan (CPT-11). J. Clin. Investig., 101: 847–
854, 1998.
64. Rivory, L. P., and Robert, J. Identification and kinetics of a -
glucuronide metabolite of SN-38 in human plasma after administration
of the camptothecin derivative irinotecan. Cancer Chemother. Pharma-
col., 36: 176–179, 1995.
65. Atsumi, R., Suzuki, W., and Hakusui, H. Identification of the
metabolites of irinotecan, a new derivative of camptothecin, in rat bile
and its biliary excretion. Xenobiotica, 21: 1159–1169, 1991.
66. Gupta, E., Lestingi, T. M., Mick, R., Ramirez, J., Vokes, E. E., and
Ratain, M. J. Metabolic fate of irinotecan in humans: correlation of
glucuronidation with diarrhea. Cancer Res., 54: 3723–3725, 1994.
67. Ciotti, M., Basu, N., Brangi, M., and Owens, I. S. Glucuronidation
of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucu-
ronosyltransferases encoded at the UGT1 locus. Biochem. Biophys. Res.
Commun., 260: 199–202, 1999.
68. Ando, Y., Saka, H., Asai, G., Sugiura, S., Shimokata, K., and
Kamataki, T. UGT1A1 genotypes and glucuronidation of SN-38, the
active metabolite of irinotecan. Ann. Oncol., 9: 845–847, 1998.
69. Iyer, L., Hall, D., Das, S., Mortell, M. A., Ramirez, J., Kim, S., di
Rienzo, A., and Ratain, M. Phenotype-genotype correlation of in vitro
SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in
human liver tissue with UGT1A1 promoter polymorphism. Clin. Phar-
macol. Ther., 65: 576–582, 1999.
70. Monaghan, G., Ryan, M., Seddon, R., Hume, R., and Burchell, B.
Genetic variation in bilirubin UDP-glucuronosyltransferase gene pro-
moter and Gilbert’s syndrome. Lancet, 347: 578–581, 1996.
71. Wasserman, E., Myara, A., Lokiec, F., Goldwasser, F., Trivin, F.,
Mahjoubi, M., Misset, J. L., and Cvitkovic, E. Severe CPT-11 toxicity
in patients with Gilbert’s syndrome: two case reports. Ann. Oncol., 8:
1049–1051, 1997.
72. Wasserman, E., Myara, A., Lokiec, F., Riofro, M., Imadalou, P.,
Bleuzen, P., Santoni, J., Trivin, F., Herait, P., Mahjoubi, M., Armand, J. P.,
Misset, J. L., and Cvitkovic, E. Bilirubin (BIL) and SN-38: pharmacoki-
netic/pharmacodynamics correlation. Ann. Oncol., 10: 58, 1998.
73. Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H.,
Yokoyama, A., Saitoh, S., Shimokata, K., and Hasegawa, Y. Polymor-
phisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a
pharmacogenetic analysis. Cancer Res., 60: 6921–6926, 2000.
74. Gupta, E., Wang, X., Ramirez, J., and Ratain, M. J. Modulation of
glucuronidation of SN-38, the active metabolite of irinotecan, by val-
proic acid and phenobarbital. Cancer Chemother. Pharmacol., 39: 440–
444, 1997.
75. Takahashi, T., Fujiwara, Y., Yamakido, M., Katoh, O., Watanabe,
H., and Mackenzie, P. I. The role of glucuronidation in 7-ethyl-10-
hydroxycamptothecin resistance in vitro. Jpn. J. Cancer Res., 88: 1211–
1217, 1997.
76. Brangi, M., Litman, T., Ciotti, M., Nishiyama, K., Kohlhagen, G.,
Takimoto, C., Robey, R., Pommier, Y., Fojo, T., and Bates, S. E.
Camptothecin resistance: role of the ATP-binding cassette (ABC), mi-
toxantrone-resistance half-transporter (MXR), and potential for glucu-
ronidation in MXR-expressing cells. Cancer Res., 59: 5938–5946,
1999.
77. Lokiec, F., Monegier du Sorbier, B., and Sanderink, G-J. Irinotecan
(CPT-11) metabolites in human bile and urine. Clin. Cancer Res., 2:
1943–1949, 1996.
78. Haaz, M-C., Rivory, L. P., Riche´, C., Vernillet, L., and Robert, J.
Metabolism of irinotecan (CPT-11) by hepatic microsomes: participa-
tion of cytochrome P-450 3A and drug interactions. Cancer Res., 58:
468–472, 1998.
79. Santos, A., Zannetta, S., Cresteil, T., Deroussent, A., Pein, F.,
Raymond, E., Vernillet, L., Risse, M. L., Boige, V., Gouyette, A., and
Vassal, G. Metabolism of irinotecan (CPT-11) by CYP3A4 and
CYP3A5 in humans. Clin. Cancer Res., 6: 2012–2020, 2000.
80. Dodds, H. M., Haaz, M-C., Riou, J-F., Robert, J., and Rivory, L. P.
Identification of a new metabolite of CPT-11 (irinotecan): pharmaco-
logical properties and activation to SN-38. J. Pharmacol. Exp. Ther.,
286: 578–583, 1998.
81. Haaz, M-C., Riche´, C., Rivory, L. P., and Robert, J. Biosynthesis of
an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidi-
no]carbonyloxycamptothecine] by human hepatic microsomes. Drug
Metab. Dispos., 26: 769–774, 1998.
82. Dodds, H. M., Wunsch, R. M., Gillam, E. M. J., and Rivory, L. P.
Further elucidation of the pathways involved in the catabolism of the
camptothecin analogue irinotecan. Proc. Am. Assoc. Cancer Res., 40:
110, 1999.
83. Rivory, L. P., Riou, J-F., Haaz, M-C., Sable, S., Vuilhorgne, M.,
Commercon, A., Pond, S. M., and Robert, J. Identification and proper-
ties of a major plasma metabolite of irinotecan (CPT-11) isolated from
the plasma of patients. Cancer Res., 56: 3689–3694, 1996.
84. Dodds, H. M., Haaz, M-C., Riou, J. F., Robert, J., and Rivory, L. P.
Identification of a new metabolite of CPT-11 (irinotecan): pharmaco-
logical properties and activation to SN-38. J. Pharmacol. Exp. Ther.,
286: 578–583, 1998.
85. Massaad, L., de Waziers, I., Ribrag, V., Janot, F., Beaune, P. H.,
Morizet, J., Gouyette, A., and Chabot, G. G. Comparison of mouse and
human colon tumors with regard to Phase I and Phase II drug-metabo-
lizing enzyme systems. Cancer Res., 52: 6567–6575, 1992.
86. Rivory, L. P., Bowles, M. R., Robert, J., and Pond, S. M. Conver-
sion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxy-
camptothecin (SN-38), by human liver carboxylesterase. Biochem.
Pharmacol., 52: 1103–1111, 1996.
87. Dresser, G. K., Spence, J. D., and Bailey, D. G. Pharmacokinetic-
pharmacodynamic consequences and clinical relevance of cytochrome
P450 3A4 inhibition. Clin. Pharmacokinet., 38: 41–57, 2000.
88. Skar, V., Skar, A. G., and Stromme, J. H. -Glucuronidase activity
related to bacterial growth in common bile duct bile in gallstone pa-
tients. Scand. J. Gastroenterol., 23: 83–90, 1988.
89. Yokoi, T., Narita, M., Nagai, E., Hagiwara, H., Aburada, M., and
Kamataki, T. Inhibition of UDP-glucuronosyltransferase by aglycons of
natural glucuronides in kampo medicines using SN-38 as a substrate.
Jpn. J. Cancer Res., 86: 985–989, 1995.
90. Sperker, B., Backman, J. T., and Kroemer, H. K. The role of
-glucuronidase in drug disposition and drug targeting in humans. Clin.
Pharmacokinet., 33: 18–31, 1997.
91. Takasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Nomura, M.,
Nagai, E., Yokoi, T., and Kamataki, T. Involvement of -glucuronidase
in intestinal microflora in the intestinal toxicity of the antitumor camp-
tothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer
Res., 56: 3752–3757, 1996.
2192 Review of CPT-11 Pharmacokinetics
92. Kase, Y., Hayakawa, T., Togashi, Y., and Kamataki, T. Relevance
of irinotecan hydrochloride-induced diarrhea to the level of prosta-
glandin E2 and water absorption of large intestine in rats. Jpn. J. Phar-
macol., 75: 399–405, 1997.
93. Araki, E., Ishikawa, M., Iigo, M., Koide, T., Itabashi, M., and
Hoshi, A. Relationship between development of diarrhea and the con-
centration of SN-38, an active metabolite of CPT-11, in the intestine and
the blood plasma of athymic mice following intraperitoneal administra-
tion of CPT-11. Jpn. J. Cancer Res., 84: 697–702, 1993.
94. Takasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Nomura, M.,
Nagai, E., Yokoi, T., and Kamataki, T. Inhibition of intestinal micro-
flora -glucuronidase modifies the distribution of the active metabolite
of the antitumor agent irinotecan hydrochloride (CPT-11) in rats. Cancer
Chemother. Pharmacol., 42: 280–286, 1998.
95. Fujisawa, T., and Mori, M. Influence of various bile salts on
-glucuronide activity of intestinal bacteria. Appl. Microbiol., 25: 95–
97, 1997.
96. Cole, C. B., Fuller, R., Mallet, A. K., and Rowland, I. R. The
influence of the host on expression of intestinal microbial enzyme
activities involved in metabolism of foreign compounds. J. Appl. Bac-
teriol., 59: 549–553, 1985.
97. Van Huyen, J. P., Bloch, F., Attar, A., Levoir, D., Kreft, C., Molina,
T., and Bruneval, P. Diffuse mucosal damage in the large intestine
associated with irinotecan (CPT-11). Dig. Dis. Sci., 43: 2649–2651,
1998.
98. Mallett, A. K., Bearne, C. A., and Rowland, I. R. The influence of
incubation pH on the activity of rat and human gut flora enzymes.
J. Appl. Bacteriol., 66: 433–437, 1989.
99. Planting, A. S. T. Modulation of irinotecan pharmacokinetics/phar-
macodynamics by combined treatment with neomycin. Proc. Am. Soc.
Clin. Oncol., 19: 1007, 2000.
100. Lokiec, F., Canal, P., Gay, C., Chatelut, E., Armand, J. P., Roche,
H., Bugat, R., Goncalves, E., and Matieu-Boue, A. Pharmacokinetics of
irinotecan and its metabolites in human blood, bile and urine. Cancer
Chemother. Pharmacol., 36: 79–82, 1995.
101. Chu, X-Y., Kato, Y., Niinuma, K., Sudo, K. I., Hakusui, H., and
Sugiyama, Y. Multispecific organic anion transporter is responsible for
the biliary excretion of the camptothecin derivative irinotecan and its
metabolites in rats. J. Pharmacol. Exp. Ther., 281: 304–314, 1997.
102. Chu, X-Y., Kato, Y., and Sugiyama, Y. Multiplicity of biliary
excretion mechanisms for irinotecan, CPT-11, and its metabolites in
rats. Cancer Res., 57: 1934–1938, 1997.
103. Chu, X-Y., Kato, Y., Ueda, K., Suzuki, H., Niinuma, K., Tyson,
C. A., Weizer, V., Dabbs, J. E., Froehlich, R., Green, C. E., and
Sugiyama, Y. Biliary excretion mechanism of CPT-11 and its metabo-
lites in humans: involvement of primary active transporters. Cancer
Res., 58: 5137–5143, 1998.
104. Gupta, E., Safa, A. R., Wang, X., and Ratain, M. J. Pharmacoki-
netic modulation of irinotecan and metabolites by cyclosporin A. Cancer
Res., 56: 1309–1314, 1996.
105. Sugiyama, Y., Kato, Y., and Chu, X-Y. Multiplicity of biliary
excretion mechanisms for the camptothecin derivative irinotecan (CPT-
11), its metabolite SN-38, and its glucuronide: role of canalicular
multispecific organic anion transporter and P-glycoprotein. Cancer Che-
mother. Pharmacol., 42: S44–S49, 1998.
106. Chu, X-Y., Kato, Y., and Sugiyama, Y. Possible involvement of
P-glycoprotein in biliary excretion of CPT-11 in rats. Drug Metab.
Dispos., 27: 440–441, 1999.
107. Paulusma, C. C., Kool, M., Bosma, P. J., Scheffer, G. L., ter Borg,
F., Scheper, R. J., Tytgat, G. N., Borst, P., Baas, P., and Oude Elferink,
R. P. A mutation in the human canalicular multispecific organic anion
transporter gene causes the Dubin-Johnson syndrome. Hepatology, 25:
1539–1542, 1997.
108. Houghton, P. J., Cheshire, P. J., Hallman, J. D., Lutz, L., Fried-
man, H. S., Danks, M. K., and Houghton, J. A. Efficacy of topoisomer-
ase I inhibitors, topotecan and irinotecan, administered at low dose
levels in protracted schedules to mice bearing xenografts of human
tumors. Cancer Chemother. Pharmacol., 36: 393–403, 1995.
109. Thompson, J., Zamboni, W. C., Cheshire, P. J., Lutz, L., Luo, X.,
Li, Y., Houghton, J. A., Stewart, C. F., and Houghton, P. J. Efficacy of
systemic administration of irinotecan against neuroblastoma xenografts.
Clin. Cancer Res., 3: 423–431, 1997.
110. Takimoto, C. H., Morrison, G., Harold, N., Quinn, M., Monahan,
B. P., Band, R. A., Cottrell, J., Guemei, A., Llorens, V., Hehman, H.,
Ismail, A. S., Flemming, D., Gosky, D. M., Hirota, H., Berger, S. J.,
Berger, N. A., Chen, A. P., Shapiro, J. D., Arbuck, S. G., Wright, J.,
Hamilton, J. M., Allegra, C. J., and Grem, J. L. Phase I and pharmaco-
logic study of irinotecan administered as a 96-hour infusion weekly to
adult cancer patients. J. Clin. Oncol., 18: 659–667, 2000.
111. Furman, W. L., Stewart, C. F., Poquette, C. A., Pratt, C. B.,
Santana, V. M., Zamboni, W. C., Bowman, L. C., Ma, M. K., Hoffer,
F. A., Meyer, W. H., Pappo, A. S., Walter, A. W., and Houghton, P. J.
Direct translation of a protracted irinotecan schedule from a xenograft
model to a Phase I trial in children. J. Clin. Oncol., 17: 1815–1824,
1999.
112. Ahmed, F., Vyas, V., Cornfield, A., Goodin, S., Ravikumar, T. S.,
Rubin, E. H., and Gupta, E. In vitro activation of irinotecan to SN-38 by
human liver and intestine. Anticancer Res., 19: 2067–2072, 1999.
113. Drengler, R. L., Kuhn, J. G., Schaaf, L. J., Rodriguez, G. I.,
Villalona-Calero, M. A., Hammond, L. A., Stephenson, J. A., Hodges,
S., Kraynak, M. A., Staton, B. A., Elfring, G. L., Locker, P. K., Miller,
L. L., Von Hoff, D. D., and Rothenberg, M. L. Phase I and pharmaco-
kinetic trial of oral irinotecan administered daily for 5 days every 3
weeks in patients with solid tumors. J. Clin. Oncol., 17: 685–696, 1999.
114. Zamboni, W. C., Houghton, P. J., Thompson, J., Cheshire, P. J.,
Hanna, S. K., Richmond, L. B., Lou, X., and Stewart, C. F. Altered
irinotecan and SN-38 disposition after intravenous and oral administra-
tion of irinotecan in mice bearing human neuroblastoma xenografts.
Clin. Cancer Res., 4: 455–462, 1998.
115. Stewart, C. F., Zamboni, W. C., Crom, W. R., and Houghton, P. J.
Disposition of irinotecan and SN-38 following oral and intravenous
irinotecan dosing in mice. Cancer Chemother. Pharmacol., 41: 259–
265, 1997.
116. Radomski, K. M., Stewart, C. F., Panetta, J. C., Houghton, P. J.,
and Furman, W. L. Phase I and pharmacokinetic study of oral irinotecan
in pediatric patients with solid tumors. Proc. Am. Soc. Clin. Oncol., 41:
592a, 2000.
117. Kobayashi, K., Bouscarel, B., Matsuzaki, Y., Ceryak, S., Kudoh,
S., and Fromm, H. pH-dependent uptake of irinotecan and its active
metabolite, SN-38, by intestinal cells. Int. J. Cancer, 83: 491–496, 1999.
118. Guichard, S., Chatelut, E., Lochon, I., Bugat, R., Mahjoubi, M.,
and Canal, P. Comparison of the pharmacokinetics and efficacy of
irinotecan after administration by the intravenous versus intraperitoneal
route in mice. Cancer Chemother. Pharmacol., 42: 165–170, 1998.
119. de Jonge, M. J. A., Sparreboom, A., Planting, A. S. T., van der
Burg, M. E. L., de Boer-Dennert, M. M., ter Steeg, J., Jaques, C., and
Verweij, J. Phase I study of 3-week schedule of irinotecan combined
with cisplatin in patients with advanced solid tumors. J. Clin. Oncol.,
18: 187–194, 2000.
120. de Jonge, M. J. A., Verweij, J., de Bruijn, P., Brouwer, E.,
Mathijssen, R. H. J., van Alphen, R. J., de Boer-Dennert, M. M.,
Vernillet, L., Jacques, C., and Sparreboom, A. Pharmacokinetic, meta-
bolic, and pharmacodynamic profiles in a dose-escalating study of
irinotecan and cisplatin. J. Clin. Oncol., 18: 195–203, 2000.
121. Shinkai, T., Arioka, H., Kunikane, H., Eguchi, K., Sasaki, Y.,
Tamura, T., Ohe, Y., Oshita, F., Nishio, M., and Karato, A. Phase I
clinical trial of irinotecan (CPT-11), 7-ethyl-10[4-(1-piperidino)-1-
piperidino]carbonyloxy-camptothecin, and cisplatin in combination
with fixed dose of vindesine in advanced non-small cell lung cancer.
Cancer Res., 54: 2636–2642, 1994.
122. Mogi, H., Hasegawa, Y., Watanabe, A., Nomura, F., Saka, H., and
Shimokata, K. Combination effects of cisplatin, vinorelbine and irino-
tecan in non-small-cell lung cancer cell lines in vitro. Cancer Che-
mother. Pharmacol., 39: 199–204, 1997.
123. Fujita, A., Takabatake, H., Tagaki, S., and Sekine, K. Phase I/II
study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in
2193Clinical Cancer Research
patients with stage IIIB and IV non-small-cell lung cancer. Cancer
Chemother. Pharmacol., 45: 279–283, 2000.
124. DeVore, R. F., Johnson, D. H., Crawford, J., Garst, J., Dimery,
I. W., Eckardt, J., Eckhardt, S. G., Elfring, G. L., Schaaf, L. J., Hanover,
C. K., and Miller, L. L. Phase II study of irinotecan plus cisplatin in
patients with advanced non-small-cell lung cancer. J. Clin. Oncol., 17:
2710–2720, 1999.
125. Kudoh, S., Fukuoka, M., Masuda, N., Yoshikawa, A., Kusunoki,
Y., Matsui, K., Negoro, S., Takifuji, N., Nakagawa, K., and Hirashima,
T. Relationship between the pharmacokinetics of irinotecan and diarrhea
during combination chemotherapy with cisplatin. Jpn. J. Cancer Res.,
86: 406–413, 1995.
126. de Jonge, M. J. A., Verweij, J., Planting, A. S. T., van der Burg,
M. E. L., Stoter, G., de Boer-Dennert, M. M., de Bruijn, P., Brouwer, E.,
Vernillet, L., and Sparreboom, A. Drug-administration sequence does
not change pharmacodynamics and kinetics of irinotecan and cisplatin.
Clin. Cancer Res., 5: 2012–2017, 1999.
127. Okamoto, H., Nagatomo, A., Kunitoh, H., Kunikane, H., and
Watanabe, K. A Phase I clinical and pharmacologic study of a carbo-
platin and irinotecan regimen combined with recombinant human gran-
ulocyte-colony stimulating factor in the treatment of patients with ad-
vanced non-small cell lung carcinoma. Cancer (Phila.), 82: 2166–2172,
1998.
128. Fukuda, M., Oka, M., Soda, H., Terashi, K., Kawabata, S., Na-
katomi, K., Takatani, H., Tsurutani, J., Tsukamoto, K., Noguchi, Y.,
Fukuda, M., Kinoshita, A., and Kohno, S. Phase I study of irinotecan
combined with carboplatin in previously untreated solid cancers. Clin.
Cancer Res., 5: 3963–3969, 1999.
129. LeBlanc, G. A., Sundseth, S. S., Weber, G. F., and Waxman, D. J.
Platinum anticancer drugs modulate P-450 mRNA levels and differen-
tially alter hepatic drug and steroid hormone metabolism in male and
female rats. Cancer Res., 52: 540–547, 1992.
130. Sasaki, Y., Ohtsu, A., Shimada, Y., Ono, K., and Saijo, N. Simul-
taneous administration of CPT-11 and fluorouracil: alteration of the
pharmacokinetics of CPT-11 and SN-38 in patients with advanced
colorectal cancer. J. Natl. Cancer Inst. (Bethesda), 86: 1096–1097,
1994.
131. Saltz, L. B., Kanowitz, J., Kemeny, N. E., Schaaf, L., Spriggs, D.,
Staton, B. A., Berkery, R., Steger, C., Eng, M., Dietz, A., Locker, P., and
Kelsen, D. P. Phase I clinical and pharmacokinetic study of irinotecan,
fluorouracil, and leucovorin in patients with advanced solid tumors.
J. Clin. Oncol., 14: 2959–2967, 1996.
132. Vanhoefer, U., Harstrick, A., Ko¨hne, C-H., Achterrath, W., Rus-
tum, Y. M., Seeber, S., and Wilke, H. Phase I study of a weekly schedule
of irinotecan, high-dose leucovorin, and infusional fluorouracil as a
first-line chemotherapy in patients with advanced colorectal cancer.
J. Clin. Oncol., 17: 907–913, 1999.
133. Benhammouda, A., Bastian, G., and Rixe, O. A Phase I and
pharmacokinetic study of CPT-11 and 5-FU (F) combination. Proc. Am.
Soc. Clin. Oncol., 16: 202, 1997.
134. Saltz, L., Shimada, Y., and Khayat, D. CPT-11 (irinotecan) and
5-fluorouracil: a promising combination for therapy of colorectal can-
cer. Eur. J. Cancer, 32A: S24–S31, 1996.
135. Adjei, A. A., Klein, C. E., Kastrissios, H., Goldberg, R. M.,
Alberts, S. R., Pitot, H. C., Sloan, J. A., Reid, J. M., Hanson, L. J.,
Atherton, P., Rubin, J., and Erlichman, C. Phase I and pharmacokinetic
study of irinotecan and docetaxel in patients with advanced solid tu-
mors: preliminary evidence of clinical activity. J. Clin. Oncol., 18:
1116–1123, 2000.
136. Asai, G., Yamamoto, N., and Sakai, S. Paclitaxel (Taxol) affects
pharmacokinetics of irinotecan and its metabolites. Proc. Am. Soc. Clin.
Oncol., 18: 201a, 1999.
137. Yamamoto, N., Negoro, S., Chikazawa, H., Shimizu, T., and
Fukuoka, M. Pharmacokinetic interaction of the combination of pacli-
taxel and irinotecan in vivo and clinical study. Proc. Am. Soc. Clin.
Oncol., 18: 186a, 1999.
138. van Zuylen, L., Verweij, J., and Sparreboom, A. Role of formu-
lation vehicles in taxane pharmacology. Investig. New Drugs, 19: 125–
141, 2001.
139. Murren, J. R., Peccerillo, K., DiStasio, S. A., Li, X., Leffert, J. J.,
Pizzorno, G., Burtness, B. A., McKeon, A., and Cheng, Y. Dose esca-
lation and pharmacokinetic study of irinotecan in combination with
paclitaxel in patients with advanced cancer. Cancer Chemother. Phar-
macol., 46: 43–50, 2000.
140. Friedman, H. S., Petros, W. P., Friedman, A. H., Schaaf, L. J.,
Kerby, T., Lawyer, J., Parry, M., Houghton, P. J., Lovell, S., Rasheed,
K., Cloughsey, T., Stewart, E. S., Colvin, O. M., Provenzale, J. M.,
McLendon, R. E., Bigner, D. D., Cokgor, I., Haglund, M., Rich, J.,
Ashley, D., Malczyn, J., Elfring, G. L., and Miller, L. L. Irinotecan
therapy in adults with recurrent or progressive malignant glioma. J. Clin.
Oncol., 17: 1516–1525, 1999.
141. Gajjar, A. J., Radomski, K. M., Bowers, D. C., Chintagumpala,
M. M., Thompson, S. J., Houghton, P. J., and Stewart, C. F. Pharma-
cokinetics of irinotecan (IRN) and metabolites in pediatric high-grade
glioma patients with and without co-administration of enzyme-inducing
anticonvulsants. Proc. Am. Soc. Clin. Oncol., 19: 162a, 2000.
142. Grossman, S. A., Hochberg, F., Fisher, J., Chen, T-L., Kim, L.,
Gregory, R., Grochow, L. B., and Piantadosi, S. Increased 9-amino-
camptothecin dose requirements in patients on anticonvulsants. Cancer
Chemother. Pharmacol., 42: 118–126, 1998.
143. Kehrer, D. F. S., Sparreboom, A., Verweij, J., de Bruijn, P.,
Nierop, C. A., van der Schraaf, J., Ruijgrok, E. J., and de Jonge, M. J. A.
Modulation of irinotecan-induced diarrhea by cotreatment with neomy-
cin in cancer patients. Clin. Cancer Res., 7: 1136–1141, 2001.
144. Chabot, G. G. Limited sampling models for simultaneous estima-
tion of the pharmacokinetics of irinotecan and its active metabolite
SN-38. Cancer Chemother. Pharmacol., 36: 463–472, 1995.
145. Sasaki, Y., Mizuno, S., Fujii, H., Ohtsu, T., Wakita, H., Igarashi,
T., Itoh, K., Sekine, I., Miyata, Y., and Saijo, N. A limited sampling
model for estimating pharmacokinetics of CPT-11 and its metabolite
SN-38. Jpn. J. Cancer Res., 86: 117–123, 1995.
146. Nakashima, H., Lieberman, R., Karato, A., Aroka, H., Ohmatsu,
H., Nomura, N., Shiraishi, J., Tamura, T., Eguchi, K., and Shinkai, T.
Efficient sampling strategies for forecasting pharmacokinetic parame-
ters of irinotecan (CPT-11): implication for area under the concentra-
tion-time curve monitoring. Ther. Drug Monit., 17: 221–229, 1995.
147. Yamamoto, N., Tamura, T., Karato, A., Uenaka, K., Eguchi, K.,
Shinkai, T., Ohe, Y., Oshita, F., Arioka, H., and Nakashima, H. CPT-11:
population pharmacokinetic model and estimation of pharmacokinetics
using the bayesian method in patients with lung cancer. Jpn. J. Cancer
Res., 85: 972–977, 1994.
148. Wasserman, E., Cuvier, C., Lokiec, F., Goldwasser, F., Kalla, S.,
Mery-Mignard, D., Ouldkaci, M., Besmaine, A., Dupont-Andre, G.,
Mahjoubi, M., Marty, M., Misset, J. L., and Cvitkovic, E. Combination
of oxaliplatin plus irinotecan in patients with gastrointestinal tumors:
results of two independent Phase I studies with pharmacokinetics.
J. Clin. Oncol., 17: 902–906, 1999.
149. Couteau, C., Risse, M. L., Ducreux, M., Lefresne-Soulas, F., Riva,
A., Lebecq, A., Ruffie, P., Rougier, P., Lokiec, F., Bruno, R., and
Armand, J. P. Phase I and pharmacokinetic study of docetaxel and
irinotecan in patients with advanced solid tumors. J. Clin. Oncol., 18:
3545–3552, 2000.
150. Masuda, N., Negoro, S., Kudoh, S., Sugiura, T., Nakagawa, K.,
Saka, H., Takada, M., Niitani, H., and Fukuoka, M. Phase I and
pharmacologic study of docetaxel and irinotecan in advanced non-small-
cell lung cancer. J. Clin. Oncol., 18: 2996–3003, 2000.
151. Ford, H. E., Cunningham, D., Ross, P. J., Rao, S., Aherne, G. W.,
Benepal, T. S., Price, T., Massey, A., Vernillet, L., and Gruia, G. Phase
I study of irinotecan and raltitrexed in patients with advanced gastroin-
testinal tract adenocarcinoma. Br. J. Cancer, 83: 146–152, 2000.
2194 Review of CPT-11 Pharmacokinetics
